Menu
Not yet recruiting NCT06851845

Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study

— Observational Kidney Diseases

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No intervention.
Who it may be relevant to
Registry conditions: Kidney Diseases. Basic parameters: 0 years — 99 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The study is planned to study specificity of the clinical course and treatment outcomes of C3 glomerulopathy (C3G) and Immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged under 18 years and 18 years and older in the Russian population in 2025-2028. The primary objective of the study is to estimate the frequency of complete or partial remission 12 months after morphological verification of the diagnosis. Assessment of demographic, clinical and laboratory, morphological characteristics at diagnosis and their relationship with the disease outcomes, primarily the disease progression and development of chronic renal failure, will allow assessing the efficacy of treatment used in real clinical practice, disease prognosis and factors associated with unfavourable outcomes.

Interventions

  • Other No intervention
    Patients will receive medical care in accordance with the routine practice of disease treatment

Primary outcome measures

  • Number and proportion of patients with overall (complete + partial) remission following the standard therapy in Russia [Time frame: 12 months]
Secondary outcome measures (12)
  • Number and proportion of patients with complete remission [Time frame: 6 months; 12 months]
  • Number and proportion of patients with partial remission [Time frame: 6 months; 12 months]
  • Number and proportion of patients with relapse [Time frame: 6 months; 12 months]
  • Number and proportion of patients with progression [Time frame: 6 months; 12 months]
  • Number and proportion of patients with progression to end-stage kidney disease [Time frame: 6 months; 12 months]
  • Number and proportion of died patients [Time frame: 6 months; 12 months]
  • Time to start of maintenance dialysis [Time frame: 6 months; 12 months]
  • Time from the diagnosis date to the start date of dialysis [Time frame: 6 months; 12 months]
  • Time from the start date of treatment to the start date of dialysis [Time frame: 6 months; 12 months]
  • Time from the diagnosis date to transplantation [Time frame: 6 months; 12 months]
  • Time from the diagnosis date to the date of complete remission [Time frame: 6 months; 12 months]
  • Time from the diagnosis date to the date of partial remission [Time frame: 6 months; 12 months]

Eligibility criteria

Inclusion criteria

  • Willing to sign informed consent form. If the patient is under 18 years of age, the parent or legally acceptable representative of the child/adolescent who can participate in this study also signs the consent form.
  • Diagnosis of primary C3G or IC-MPGN confirmed by the results of morphological and clinical studies.
  • The results of serum creatinine level, proteinuria determination obtained not earlier than 4 weeks before the kidney biopsy
  • Index date (kidney biopsy) not earlier than March 2024 and not later than 11 months before signing the ICF
  • The estimated baseline GFR (using the CKD-EPI formula for persons aged over 18 years and the modified Schwarz formula for children) or the measured GFR is ≥30 mL/min per 1.73 m2.

Exclusion criteria

  • Patients participating in a clinical trial with the investigational product.
  • Patients with monoclonal gammopathies (myeloma, B-cell lymphoma/lymphocytic leukemia, lymphoplasmacytoma)
  • Patients with systemic autoimmune diseases and vasculitis (systemic lupus erythematosus, systemic sclerosis, dermatomyositis, mixed connective tissue disease, Sjogren syndrome, Henoch-Schönlein purpura, ANCA vasculitis, cryoglobulinemia)
  • Patients with current or recent infections (viral hepatitis B, viral hepatitis C, infective endocarditis or sepsis, infected ventriculoatrial shunts, abscesses, meningococcal and other bacterial infections, protozoan infections)
  • Patients with any clinically significant acute disease within 30 days prior to kidney biopsy
  • Clinically significant concomitant kidney disease
  • Treatment with pegcetacoplan

Other protocol-defined inclusion/exclusion criteria may apply.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06851845 · CLNP023B1RU01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗